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Abstract
Background: Altered expression profiles of microRNAs (miRNAs) are linked to many diseases including lung cancer.
miRNA expression profiling is reproducible and miRNAs are very stable. These characteristics of miRNAs make them
ideal biomarker candidates.
Method: This work is aimed to detect 2-and 3-miRNA groups, together with specific expression ranges of these
miRNAs, to form simple linear discriminant rules for biomarker identification and biological interpretation. Our
method is based on a novel committee of decision trees to derive 2-and 3-miRNA 100%-frequency rules. This
method is applied to a data set of lung miRNA expression profiles of 61 squamous cell carcinoma (SCC) samples and
10 normal tissue samples. A distance separation technique is used to select the most reliable rules which are then
evaluated on a large independent data set.
Results: We obtained four 2-miRNA and three 3-miRNA top-ranked rules. One important rule is that: If the expression
level of miR-98 is above 7.356 and the expression level of miR-205 is below 9.601 (log2 quantile normalized MirVan
miRNA Bioarray signals), then the sample is normal rather than cancerous with specificity and sensitivity both 100%. The
classification performance of our best miRNA rules remarkably outperformed that by randomly selected miRNA rules. Our
data analysis also showed that miR-98 and miR-205 have two common predicted target genes FZD3 and RPS6KA3, which
are actually genes associated with carcinoma according to the Online Mendelian Inheritance in Man (OMIM) database.
We also found that most of the chromosomal loci of these miRNAs have a high frequency of genomic alteration in lung
cancer. On the independent data set (with balanced controls), the three miRNAs miR-126, miR-205 and miR-182 from our
best rule can separate the two classes of samples at the accuracy of 84.49%, sensitivity of 91.40% and specificity of 77.14%.
Conclusion: Our results indicate that rule discovery followed by distance separation is a powerful computational
method to identify reliable miRNA biomarkers. The visualization of the rules and the clear separation between the
normal and cancer samples by our rules will help biology experts for their analysis and biological interpretation.
Background
miRNAs are a class of small (19-25 nucleotides) and endo-
genous non-coding RNAs which play important roles in
various biological processes [1-7]. For example, miRNAs
can regulate gene expression at the post-transcriptional
stage, and can control fundamental cellular processes such
as differentiation, cell growth, proliferation and apoptosis
[1,3,4,7,8]. In fact, miRNAs have the potential to regulate
at least 20-30% of all human transcripts [6,9-11]. They
have also been shown to control the expression of onco-
genes and tumor-suppressor genes [4,12-14]. Aberrant
miRNA expressions have been linked to many diseases,
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and have been intensively investigated recently to discover
miRNA biomarkers for the diagnosis of diseases including
lung cancer [10,15-17]. The inherent stability of miRNAs
in serum and the reliability and reproducibility of expres-
sion analysis [5,9,18-21] make them ideal candidates for
biomarkers [22].
However, recent studies have often focused on statistical
and biological significance of single miRNAs by identifying
differentially expressed individual miRNAs as biomarkers
[23]. The problem is that single-miRNA rules are insuffi-
cient for accurate diagnosis [24]. For example, Raponi et
al. [10] identified 15 miRNAs differentially expressed
between normal and squamous cell carcinoma (SCC) sam-
ples. None of them has good sensitivity. This is probably
because target mRNAs are actually affected simultaneously
by multiple miRNAs [25,26] synergistically or possibly sev-
eral miRNAs-regulated pathways are involved in the pro-
gression of the disease [27].
Lung cancer is often diagnosed at a late stage with poor
prognosis [27,28]. It is also the leading cause of cancer-
related deaths worldwide [27]. Non-small cell lung cancers
(NSCLC) are the major types of lung cancer, comprised
mainly of adenocarcinoma and SCC. Algorithms to diag-
nose early-stage SCC are vital for improving the survival
rate of the patients [29]. Chest X-ray has been applied for
its early detection, but it has low sensitivity [30-33]. Other
studies have identified gene mutation spectra and gene
expression profiles associated with biological processes
that are altered in lung cancer [3,34], resulting in
improved sensitivity. As miRNAs are promising biomarker
candidates [35], we specially use miRNA groups to form
simple and strong rules for accurate diagnosis and hope-
fully accurate early diagnosis to SCC.
This work developed a novel method to find small num-
bers of miRNAs that are able to separate healthy samples
from SCC samples with clear and wide margin in 2D or
3D spaces. Our method was tested on the SCC miRNA
expression data set from [10]. Many 2-and 3-miRNA
groups (together with their specific expression ranges)
were discovered as clear linear discriminant rules for the
diagnosis of SCC. The basic idea of our method is the con-
struction of an innovative committee of decision trees by
using the C4.5 algorithm [36] iteratively. The preprocess
of the data involves a prioritization method to rank the
whole number of miRNAs and then to focus on potential
candidates by projecting wet-lab confirmed plasma and
tissue miRNA biomarkers onto this ranked list of miRNAs
ordered by miRNAs’ gain ratio [37]. This feature selection
method is capable of recommending those highly ranked
miRNAs not yet studied by wet-labs in the past for rule
discovery, and capable of suggesting a good mapping
between lung tissue-specific and plasma-specific miRNA
biomarkers useful for a minimally invasive diagnosis. For
the discovery of the most reliable rules, a distance
separation technique is used to determine the Max-Min
distance between the normal and cancer classes separated
by each rule, and the widest distance is then taken to
recommend the best rules. In addition, we also considered
a computationally heavy method to detect rules from the
whole feature space. We further demonstrated the reliabil-
ity of these biomarkers by comparing the performance of
the most reliable 2-miRNA (3-miRNA) rules with that of
1000 randomly selected 2 miRNAs (3 miRNAs) with C4.5
decision tree classifier and 10-fold cross validation, and
performing a resampling test by disordering the class
labels.
For all of the miRNAs involved in our 2-miRNA rules,
we examined their chromosomal locations and their com-
mon target genes. We also established links between the
diseases and chromosomal locus with the common target
genes to show that most of the chromosomal loci have a
high frequency of genomic alteration in lung cancer and
that two sets of our biomarkers have confirmed associa-
tions with lung cancer.
Materials and methods
Data sets of miRNA expressions in SCC patients
Two data sets are used by this work. Data set 1 is a collec-
tion of miRNA expressions in SCC tissues which had been
studied by [10] for comparative analysis of differentially
expressed miRNAs between normal and SCC tissues.
Here, it is used for rule discovery. In this data set, there
are 61 SCC tissue samples and 10 matched adjacent nor-
mal lung tissue samples for the miRNA expression profil-
ing. These samples were collected from patients in the
University of Michigan Hospital between October 1991
and July 2002 with patient consent and institutional review
board approval. Total RNAs of these 71 samples were pre-
processed and then profiled on MirVan miRNA Bioarray
(version 2, Ambion) which contains 328 human miRNA
probes. So, this data set is a 71 × 328 relational table with
each row associating with a class label “cancer” or “nor-
mal”. The original miRNA expression data was normalized
by the quantile and log2 methods, and it was stored at the
National Center for Biotechnology Information (NCBI)
Gene Expression Omnibus [38] under the accession num-
ber GSE16025.
Data set 2 [16] is used as an independent data set to
assess the importance of our rules. Data set 2 comprises
187 cancer tissues and 174 adjacent normal tissue from
patients described by the expression levels of 549 miR-
NAs. The expression levels in this data set were pro-
cessed by subtracting the background as average values
of the replicate spots of each miRNA and filtering out
the expression signal of faint spots below 600. This data
set can be downloaded from the Gene Expression
Omnibus under the accession number GSE15008. Since
it is impossible to confirm the 34 paired cancerous and
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adjacent normal samples described by [16] from all the
published studies, we are unable to choose this large
sample size as the training set.
Rule discovery within top-ranked miRNAs
We discover simple rules in the form:
a1 ≤ x1 ≤ b1 ∩ a2 ≤ x2 ≤ b2 (1)
where x1 and x2 represent two miRNAs, [a1, b1] is the
expression range of x1, and [a2, b2] is the expression range
of x2 (a1 and a2 can be −∞; b1 and b2 can be +∞; one of a*
and b* must be infinite). If every cancer sample’s expres-
sion profile satisfies (falls into) the two specific expression
ranges, but none of the normal sample profiles satisfies,
then we say it is a 100%-frequency rule to differentiate the
cancer samples from the normal samples. The complete
form of this rule is denoted by
a1 ≤ x1 ≤ b1 ∩ a2 ≤ x2 ≤ b2 → cancer (100%) (2)
It can be suggested that if the expression of x1 is
between a1 and b1 for a test lung cell sample, and the
expression of x2 is between a2 and b2, then this test sample
is very likely to be a cancer cell. Similarly in this work, we
also define a 100%-frequency rule to differentiate normal
samples from cancer samples. Such strong rules can be
easily visualized in 2D spaces to facilitate biological inter-
pretation of the computational results.
This work focuses on 2-miRNA or 3-miRNA 100%-fre-
quency rules as biomarkers for the diagnosis of SCC. We
do not identify 100%-frequency rules with 4 or 4+ miRNAs.
Our rule discovery method is based on decision trees which
usually generate rules combining 2 or 3 miRNAs with their
specific expression ranges. Decision tree is a classical idea
to induce a set of exclusive rules covering the training data
only once, and thus the rules are sensitive to slight change
of training data. Due to this constraint, using a single deci-
sion tree usually loses some prediction accuracy [39].
Our method has two innovative parts. One is a novel
idea to generate a committee of decision trees to dis-
cover 100%-frequency rules; the other is a simple pro-
jection method to narrow down important miRNAs
from the 328 miRNAs for the induction of the decision
tree ensemble.
As the first step of the projection method, we prioritize
and rank the 328 miRNAs in the data set based on their
gain ratios over the 71 samples’ expression profiles. Gain
ratio [37] measures a collective difference of every single
miRNA’s expressions between the two classes. A high gain
ratio indicates that the miRNA is a high-potential biomar-
ker differentially expressed over the two classes. As the
second step, we project wet-lab confirmed and intensively
studied miRNAs onto this rank list. Using this step, we
can recommend those highly ranked miRNAs that have
not been studied in wet-labs in the past for rule discovery
and potentially for fresh biological study.
In this work, we use 5 plasma biomarkers (miR-486,
miR-126, miR-182, miR-210 and miR-21) identified in
28 NSCLC patients including 14 adenocarcinoma and
14 SCC patients [15] for the above rank list projection.
All of these miRNAs are confirmed as key biomarkers
in early lung cancer diagnosis. These miRNAs in plasma
are also a subset of 12 previously identified tissue bio-
markers validated by paired SCC tissues and noncancer-
ous tissues associated with early-stage lung cancer [40].
So these 5 miRNAs can serve as a guideline for the next
step of tissue-specific biomarkers identification.
The projection of the 5 plasma biomarkers against the
list of prioritized 328 miRNAs is shown in Table 1. The
5 confirmed miRNAs are mapped to positions 1, 3, 5,
13 and 19. However, none of these 19 individual miR-
NAs is a good biomarker to separate the two classes of
data as shown in Figure 1. So, we concentrate on the
entire expression data of these 19 miRNAs to derive
groups of miRNAs for 100%-frequency rules. The
remaining data (i.e., excluding the 19 miRNAs) is used
Table 1 Projection of 5 important miRNAs onto a prioritized list of 328 miRNAs, resulting in 19.
miRNA Rank Expression P-value miRNA Rank Expression P-value
miR-486 1 Down 3.12e-05 miR-125a 11 Down 8.857e-02
miR-98 2 Down 4.631e-07 miR-93 12 Up 6.401e-06
miR-126 3 Down 1.14e-02 miR-210 13 Up 5.548e-12
miR-205 4 Up 3.678e-07 miR-224 14 Up 2.866e-14
miR-182 5 Up 2.2e-16 miR-17-5p 15 Up 3.646e-11
miR-106b 6 Up 1.224e-09 miR-373-AS 16 Down 3.647e-03
miR-133a 7 Down 4.208e-03 miR-483 17 Down 4.11e-02
miR-513 8 Down 2.263e-02 miR-139 18 Down 3.812e-03
miR-451 9 Down 2.713e-05 miR-21 19 Up 1.293e-04
miR-331 10 Up 4.124e-02
miRNAs ranked as high as these 5 miRNAs
Song et al. BMC Genomics 2014, 15(Suppl 9):S16
http://www.biomedcentral.com/1471-2164/15/S9/S16
Page 3 of 11
for comparison to examine the effectiveness of our rule
discovery method.
To construct a committee of decision trees for the dis-
covery of multiple 100%-frequency rules, we induce the
first decision tree from the 19-miRNA data set. To induce
the second tree, we remove the field (attribute values from
the data) of the root node miRNA of the first tree from
the data set. Iteratively, we construct a subsequent deci-
sion tree by removing the data of the root node miRNA of
the current tree. This process continues until there are
only two miRNAs left in the data set. We use the R soft-
ware package [41] and its C4.5 implementation to con-
struct each decision tree (The source code of algorithm
constructing a committee of decision trees is described in
the Additional file 1).
Every 100%-frequency rule with two or three miRNAs
can separate the cancer samples clearly from the normal
samples in 2D or 3D spaces. As a wider separation suggests
a more reliable biomarker rule (Figure 2), we measure the
separation extent by using the shortest pair-wise Euclidean
distance between the cancer and normal samples. When
multiple 100%-frequency rules are generated, further data
analysis is on those with a wider separation distance (i.e.,
the Max-Min distance).
The entire work flow of our rule discovery method with
feature space projection is summarized in Figure 3. The
best two or three miRNA biomarkers identified by our
method cannot produce an accuracy of 100% by using
simple linear discriminant analysis of support vector
machine.
Rule discovery across the whole feature space
Our feature ranking and projection method is good to
select important miRNAs to derive 100%-frequency rules.
However, some bias may occur as our list of “extensively
studied miRNAs in the literature” may be far from
complete. To ensure there is less bias, we search the
whole feature space, namely across all of the 328 miRNAs,
to find strong rules. However, the exploration of every
possible combination of these 328 miRNAs leads to expo-
nentially computational cost.
Therefore, our method is restricted to combine all possi-
ble 2-and 3-miRNAs and all possible valid expression
ranges of these miRNAs to see whether the combined
ranges satisfy every cancer sample’s expression profile. If
this is true, we then examine whether the combined
ranges do not satisfy any of the normal samples. If this
comes true as well, then the combined expression ranges,
together with the miRNAs, form a 100%-frequency rule to
distinguish all of the cancer samples from all of the normal
samples in 2D or 3D spaces. Similarly, we detect such
rules to distinguish 100% of the normal samples from the
cancer samples. We also use the distance separation tech-
nique to identify more reliable rules.
Figure 2 Distance separation by 100%-frequency rules in 2D
space. The left panel shows a shorter distance separation between
the cancer and normal samples than the separation shown in the
right panel.
Figure 1 Heatmap representation of the expression levels of
the 19 miRNAs. A single miRNA is unable to distinguish cancer
samples from normal samples, while combining 2 or 3 miRNAs can
identify cancer (or normal) samples from the normal (or cancer)
samples without mistake.
Figure 3 The procedure of rule discovery with 19 miRNAs. The
up panel is the dataset processing phase, and 19 miRNAs are
obtained. The down panel is the discovery phase to get biomarkers.
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Results
Our results are presented in five parts. The first part
reports 2-miRNA and 3-miRNA rules and classification
performance. The second part is related to distance
separation of the rules in 2D or 3D spaces. The third part
illustrates the reliability of the identified best miRNA
rules. The fourth part presents the chromosomal locations
of the miRNAs, and the last part is related to association
studies between miRNA biomarkers and disease genes.
Prediction performance by rules
Comparison with literature methods
To show the effectiveness of our feature projection
method on prediction accuracy, we compared the predic-
tion performance of three commonly used classifiers on
four data sets. One is the data set prepared by [10] which
consists of 15 differentially expressed miRNAs extracted
from the initial 328 miRNAs. The second data set contains
only the 5 plasma miRNAs [15] which we used to project
out our top-ranked 19 miRNAs. The third data set is our
data set consisting of the 19 top-ranked miRNAs (Table
1). The fourth data set contains all the data after the
removal of the third data set (the 19-miRNA data set)
from the 328-miRNA data set. Note that there is not
much miRNA overlapping between the first and third data
set (only 6 miRNAs in common). We used k-nearest
neighbor classifier (KNN, k = 1), Naive Bayes (NB), and
C4.5 decision tree (C4.5) classifier to conduct the predic-
tion under a 10-fold cross-validation scheme.
Table 2 shows the prediction performance (specificity,
sensitivity, F1 measure and ROC area) of the three classi-
fiers on these four data sets. It can be seen that the three
classifiers all performed better on the 5-plasma miRNAs
data set and on our 19-miRNA data set than on the other
two data sets. This indicates that the 5 plasma biomarkers
are indeed good biomarkers, and the 19 prioritized and
projected miRNAs are indeed good potential candidates
for rule discovery and biomarker identification.
Multiple rules derived from the top-ranked 19 miRNAs
We applied C4.5 to our 19 top-ranked miRNAs data set to
construct the first decision tree (denoted by DT1). As
described in the Method section, we then removed the
root node miRNA of DT1 from the data set to construct
the second tree (denoted by DT2). By iteration, we con-
structed a total of 18 decision trees. Interestingly, DT1
does not contain any 100%-frequency rules. In fact, 6 of
the 18 decision trees (DT2, DT3, DT4, DT9, DT10, and
DT15) produce an accuracy of 100% consisting of 2 or 3
miRNAs. Only three decision trees (DT2, DT3 and DT4)
are able to form the 100%-frequency biomarker rules.
As an example, Figure 4 displays the tree structures of
DT2 and DT4. Both of them contain only two miRNAs.
The 100%-frequency rules derived from these two trees
separate the cancer and normal samples in a way as
shown in Figure 5 where the x-y axis of the 2D planes
represents the expression ranges of these miRNAs.
Classification performance under 5-fold training-test
experiments
The derived rules above can separate the two classes of
samples clearly without any mistake. However, they are
derived from the top-ranked miRNAs based on all of the
71 samples. To demonstrate the generalization ability of
the rules induced by our method, we conducted C4.5’s 5-
fold training-test experiments. The initial 10 normal sam-
ples and 61 cancerous samples are randomly divided into
5 parts. Four parts of the data set were used as a training
data set, and 5 training data sets were constructed (TrS1,
TrS2, TrS3, TrS4 with 57 samples, and TrS5 with 56 sam-
ples). Correspondingly, the remaining part was reserved as
a test data set, and 5 test data sets were constructed
(TeS1, TeS2, TeS3, TeS4 with 14 samples, and TeS5 with
15 samples, each containing two normal samples). By our
Table 2 Comparisons of three classifiers on four data sets.
Data sets Algorithms Specificity Sensitivity F-Measure ROC Area
15 miRNAs (Raponi et al. 2009) KNN 0.9833 0.8182 0.975 0.934
NB 0.9833 0.8182 0.975 0.934
C4.5 0.9516 0.7778 0.959 0.827
5 miRNAs (Shen et al. 2010) KNN 0.9839 1.0000 0.992 0.944
NB 0.9839 1.0000 0.992 0.989
C4.5 0.9672 0.8000 0.967 0.84
19 miRNAs (top ranked) KNN 0.9839 1.0000 0.992 0.944
NB 0.9836 0.9000 0.984 0.946
C4.5 0.9524 0.8750 0.968 0.798
309 miRNAs (lower ranked) KNN 0.9833 0.8182 0.975 0.926
NB 0.8413 0.6250 0.935 0.779
C4.5 0.8413 0.3846 0.891 0.666
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method, the gain ratio and the 5 plasma miRNAs projec-
tion method were applied to select miRNAs from the 5
training sets. Actually we obtained 27, 21, 14, 32, and 20
top-ranked miRNAs respectively. Then the rules were
derived within these top-ranked miRNAs and the Max-
min distance step was applied to determine the most reli-
able rule. The TrS1, TrS2, TrS4, and TrS5 training data
sets have the same best rule (made from miR-205 and
miR-451), while the TrS3 has the rule made from miR-205
and miR-21. Finally, we applied these reliable rules to the
corresponding test sets, and all achieved an accuracy of
100%, except TeS4 with 92.86% (1 cancer sample misclas-
sified). The details are described in Additional file 2.
Assessing the importance of miRNA biomarkers by using an
independent data set
Data set 2 [16] contains miRNA expression data of 187
cancer tissues and 174 adjacent normal tissue from
patients. The platform for generating data set 2 (the
National Engineering Research Center mammalian micro-
RNA microarray with 549 human miRNAs) is different
from the platform of data set 1 (MirVan miRNA Bioarray,
version 2). The two data sets are preprocessed by different
methods as well. Because of these differences, it is not
reasonable to directly test the miRNA expression ranges
on data set 2 for a rule derived from data set 1. However,
the miRNAs in a rule of data set 1 can be still validated on
the data set 2 by testing whether these miRNAs are able to
classify the samples in data set 2 with a high accuracy. A
high classification performance would suggest that these
miRNAs are robust across different data sets and thus
they are worth of further investigation. We note that the
miRNAs in a rule from data set 1 is detected indepen-
dently from data set 2.
To test whether these miRNA biomarkers discovered
from data set 1 have a good generalization ability, we car-
ried out 10-fold cross-validation on the expression data of
only these miRNAs of data set 2 (the independent data
set) to see the classification performance in C4.5. We
compared the sensitivity, specificity, accuracy, ROC area
and F-measure for three data sets: data set 2 of 549 miR-
NAs, the data set of top-ranked 158 miRNAs, and the data
set of 3 miRNAs (miR-126, miR-205 and miR-182) which
are from the best rule from data set 1 (with the largest dis-
tance 0.7799). The classification performance on these
three data sets are shown in Table 3. We can see that the
classification using just the 3 miRNAs from the best rule
of data set 1 achieved an accuracy of 84.49%, sensitivity of
91.40% and specificity of 77.14%. This performance is bet-
ter than the classification performance by using all miR-
NAs in data set 2. Although the specificity decreases, the
cost in real-life diagnostic would be lower using the just 3
miRNAs, because the cost of misclassifying ‘normal’ as
‘cancer’ is much smaller than misclassifying ‘cancer’ as
‘normal’. These results demonstrate that the miRNA bio-
markers identified from data set 1 are also biomarkers to
separate the two classes of samples in the independent
data set 2 with a high accuracy. This implies that our
miRNA biomarkers have a good generalization ability in
classification.
Rules derived by using the whole feature space
On the whole feature space, our rule mining method
detected a total of 14 new 100%-frequency rules each of
which combines only two or three miRNAs, in addition to
the 3 rules identified by the decision tree committee. Two
of them are displayed in Figure 6. The rules are: −∞ < let −
7a ≤ 11.989 ∩ −∞ < miR − 205 ≤ 9.601® Normal(100%) (
−∞ and +∞ can be omitted.); 7.755 ≤ miR − 103 < +∞ ∩ −∞
Figure 4 Decision trees. The left panel is a decision tree made of
miR-205 and miR-98. The right panel is a decision tree made of
miR-205 and miR-451.
Figure 5 Expression data on 2D planes. The left panel is the
plane co-ordinated by miR-205 and miR-98. The right panel is
coordinated by miR-205 and miR-451. The blue boundaries indicate
the expression ranges of all of the normal samples.
Table 3 The performance comparison of three datasets.
Data sets Sensitivity Specificity Accuracy ROC
area
F-
measure
549
miRNAs
0.8441 0.8343 0.8393 0.817 0.844
158
miRNAs
0.8656 0.8111 0.8393 0.845 0.847
3 miRNAs 0.9140 0.7714 0.8449 0.853 0.859
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<miR − 126 ≤ 8.825® Cancer(100%). Again, it can be seen
that these two sets of biomarkers are able to distinguish the
71 cancer and normal samples with no mistake. Examples
of 3-miRNA 100%-frequency rules are shown in Figure 7.
The rules are: −∞ < miR − 133a ≤ 5.844 ∩ 7.381 ≤ miR −
21 < +∞ ∩ −∞ < miR − 520a − AS ≤ 5.229 ® Cancer
(100%); −∞ < miR − 100 ≤ 8.706 ∩ −∞ < miR − 199a ≤
7.091 ∩ −∞ <miR − 200c ≤ 9.890® N ormal(100%).
Distance separation in 2D and 3D spaces to identify
reliable biomarkers
We calculated the Euclidean distance for the rules discov-
ered from the whole data set 1 (i.e., the 71 samples), and
used the shortest pair-wise distance and the Max-Min
technique to identify the best miRNA biomarkers (Table
4). In our method, we selected top × significant rules, and
× is the ceiling of the 1/3 of the total number of rules.
Therefore, we selected top four 2-miRNA rules with the
distance cut-off threshold 0.20 and top three 3-mIRNA
rules with the cut-off threshold 0.45.
From Table 4, it can be seen that miR-205 and miR-98
constitute our best 2-miRNA rule that
7.356 ≤ miR − 98 < +∞ ∩ −∞ < miR − 205 ≤ 9.601 → Normal (100%) (3)
for the diagnosis of SCC. In fact, this rule separates
the normal and cancer classes with a distance of at least
0.5421 in 2D space. Their chromosomal locations, com-
mon target genes, and associations with disease genes
are presented in later part.
Classification performance on the data of only these
two miRNAs was also evaluated. The performance (F1
Measure: KNN-1.000, NB-0.984, C4.5-0.976) is higher
than that on the 19-miRNA data set, or on the 15-
miRNA data set (Table 2).
The other three important 2-miRNA rules are formed
by miR-205 and miR-451, by miR-103 and miR-126, or by
let-7a and miR-205. The best 3-miRNA rule is formed by
miR-126, miR-205 and miR-182; the second best is by
miR-100, miR-199a and miR-200c; and the third best is by
miR-133a, miR-21 and miR-520a-AS. Table 5 shows the
details of the rules of these best 2-and 3-miRNA biomar-
kers including their expression ranges.
The reliability of identified best 2-miRNA and 3-miRNA
biomarkers
We applied 10-fold cross-validation test on the best 2-
miNRA (miR-205 and miR-98) and 3-miRNA rules (miR-
126, miR-205 and miR-182) to see the classification perfor-
mance by C4.5 (R package RWeka). We further performed
a randomization test to see whether the best 2-miRNA (or
3-miRNA) miRNAs are better predictors than randomly
selected 2 miRNAs (or 3 miRNAs). The random selection
was repeated 1000 times. All the area under ROC curves
(AUCs) were calculated and compared. The best 2-miNRA
rule had an average AUC = 1.0 in the 10-fold cross-valida-
tion, and the best 3-miRNA rule had an average AUC =
0.9975. For the randomly selected 2 miRNAs, only a prob-
ability of 0.007 could produce an AUC≥0.999 for the 1000
repeated tests. For the randomly selected 3 miRNAs, only
a probability of 0.012 could produce an AUC≥0.9975. The
probabilities in different AUC scales are shown in Table 6.
These results indicate that our miRNA biomarkers are sig-
nificant and reliable, instead of random. We further per-
formed a resampling test by disordering the class labels,
and no rules were found using our method.
The genomic location of biomarker miRNAs
Many known human miRNAs reside in particular geno-
mic regions that are prone to alteration in cancer cells.
For example, the main chromosomal alteration loci of
miR-15 and miR-16 are identified at 13q14 with down-
regulation, which is the first association study between
miRNA genes and cancer [42,43]. We obtained the
chromosomal locations of all of the 13 miRNAs in the
100%-frequency rules of a wide separation in 2D and 3D
Figure 6 Examples of 2-miRNA rules. The left panel describes
two miRNAs whose class-label is related with normal. The right
panel shows two miRNAs whose class-label is related to cancer.
Figure 7 Examples of 3-miRNA rules. The left panel contains miR-
100, miR-199a and miR-200c. The right panel contains miR-133a,
miR-21 and miR-520a-AS.
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spaces (the 7 top-ranked rules in Table 4). This location
information was obtained through keyword search from
the miRNAMap database [44] and miRBase database
[45-47]. For the miRNAs let-7a, miR-133a and miR-
199a, we obtained three loci for each of them. Details
are presented in Table 7.
It has been previously reported that there are many chro-
mosomal arms having frequent loss of heterozygosity [48],
such as 1p, 3p, 4p, 4q, 5q, 8p, 9p (p16), 9q, 10p, 10q, 13q
(Rb), 15q, 17p (p53), 18q, 19p, Xp, and Xq, in frequency
order for lung cancer [9,45,46,49]. In this study, we identi-
fied some new chromosomal arms such as 11q, 22q, 17q,
20q, 1q and 12p. In particular, the best 2-miRNA rule bio-
markers miR-98 and miR-205 are located at Xp11.2 and
the new arm 1q32.2. In fact, these two arms have been stu-
died before for various purposes. It was reported by [50]
that there are 5 cases of renal cell carcinoma with translo-
cation involving Xp11.2 in children. It was found by [51]
that chromosome 1q32.2, based on an alignment of the
mature miR-205, controlled epithelial-to-mesenchymal
transition. It was also claimed by [52] that renal cell carci-
nomas are associated with Xp11.2 translocation in five
adult patients. Sham et al. [53] identified several nonran-
dom chromosomal changes in 31 primary ovarian carcino-
mas in Chinese women, including gains of 1q (10 cases,
32%), and that the losses of 1q32.2 were observed as altera-
tions in comparative genomic hybridization studies. These
results showing the alterations of these two locations in
cancers support our suggestion that combining miR-98
and miR-205 is a good approach to lung cancer study.
Target genes of biomarker miRNAs and their associated
diseases
For each 100%-frequency rule containing 2 or 3 miR-
NAs, we detected target mRNAs of these miRNAs.
Then we identified their common targets. From these
Table 4 Shortest pair-wise Euclidean distance between the cancer and normal samples in 2-miRNA and 3-miRNA
biomarker spaces.
Biomarker miRNAs in the Rules Shortest Distance Rank
2-miRNA
biomarker
miR-205 and miR-98 0.5421 2D.1
miR-205 and miR-451 0.4311 2D.2
miR-103 and miR-126 0.3591 2D.3
let-7a and miR-205 0.2496 2D.4
miR-210 and miR-98 0.1892 2D.5
miR-137 and miR-98 0.1660 2D.6
miR-106b and miR-29b 0.1498 2D.7
miR-17-5p and miR-451 0.1398 2D.8
miR-149 and miR-182 0.0941 2D.9
miR-324-3p and miR-43 0.0879 2D.10
let-7b and miR-486 0.0835 2D.11
3-miRNA biomarker miR-126, miR-205 and miR-182 0.7799 3D.1
miR-100, miR-199a and miR-200c 0.7275 3D.2
miR-133a, miR-21 and miR-520a-AS 0.4515 3D.3
miR-133b, miR-139 and miR-210 0.2459 3D.4
miR-1, miR-106a and miR-203 0.1589 3D.5
let-7i, miR-130a and miR-224 0.1231 3D.6
Table 5 Important 2-miRNA and 3-miRNA rules by using the shortest pair-wise distance and the Max-Min technique.
miRNA biomarkers Their expression ranges and the rules
miR-98 and miR-205 7.356 ≤ miR − 98 < +∞ ∩ −∞ < miR − 205 ≤ 9.601 ® N ormal(100%)
miR-451 and miR-205 6.148 ≤ miR − 451 < +∞ ∩ −∞ < miR − 205 ≤ 9.601 ® N ormal(100%)
let-7a and miR-205 −∞ < let − 7a ≤ 11.989 ∩ −∞ < miR − 205 ≤ 9.601 ® N ormal(100%)
miR-103 and miR-126 7.755 ≤ miR − 103 < +∞ ∩ −∞ < miR − 126 ≤ 8.825 ® Cancer(100%)
miR-126, miR-205 and miR-182 −∞ < miR − 126 ≤ 8.825 ∩ 5.354 ≤ miR − 205 < +∞ ∩5.551 ≤ miR − 182 < +∞ ® Cancer(100%)
miR-133a, miR-21 and miR-520a-AS −∞ < miR − 133a ≤ 5.844 ∩ 7.381 ≤ miR − 21 < +∞ ∩ − ∞ < miR − 520a − AS ≤ 5.229 ® Cancer(100%)
miR-100, miR-199a and miR-200c −∞ < miR − 100 ≤ 8.706 ∩ −∞ < miR − 199a ≤ 7.091 ∩ − ∞ < miR − 200c ≤ 9.890 ® N ormal(100%)
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common targets, we also linked to the OMIM disease
database to examine disease gene information.
The target genes of the miRNAs in the 4 top-ranked
2-miRNA rules (Table 4) were extracted from the Tar-
getscanHuman database [54,55]. All of them have many
target genes. For example, miR-451, -126, -98, -205,
-103 and let-7a have 20, 25, 46, 415, 531 and 84 target
genes respectively. Then we looked at the common tar-
get genes of the miRNAs involved in one rule. Interest-
ingly, the common targets are not many. For example,
miR-98 and miR-205 have only two common targets
FZD3 and RPS6KA3. Details are shown in Table 8.
The first and third top-ranked miRNA pairs (Table 8)
have opposite change of expression in normal samples
compared to the disease samples. These pairs of miRNA
may effect different complementary pathways. It is pos-
sible that the down regulated miRNA inhibited a tran-
scription factor that regulates the other miRNA. On the
other hand, the common targets of the pairs of miRNAs
are sensible only when (i) down-regulation of their com-
mon targets causes cancers, and (ii) their common tar-
gets have normal or high expression in normal tissues.
For example, NKD1, FZD2 and EPB41 fit the biological
behavior expected above. Especially, down regulation of
NKD1 (common target of let-7a and miR-205) increases
invasive potential of NSCLC [56]. FZD3 works the same
way ("The proliferation and invasion ability of SACC-M
cells were enhanced when the expressions of FZD2 and
FZD3 genes were inhibited in SACC-M cells”) [57].
EPB41 (common target of let-7a and miR-205) is
another example that works this way. It is absent in
most NSCLC cancer. Its presence suppresses these lung
cancer cells’ growth [58].
From these target genes, we further conducted disease
gene analysis. First, we obtained the common target genes’
OMIM information and their associated diseases from
Human Disease Gene List [59] with the target genes’
name. To this end, we compared the associated diseases of
these biomarkers. It was found that: (i) the two miRNAs
(miR-98 and miR-205) involved in our best rule have been
both confirmed to associate with carcinoma; and (ii) Let-
7a and miR-205 (in the second best rule) have been con-
firmed to be directly associated with lung cancer. On the
other hand, we did not find evidence in the literature to
show the pair miR-451 and miR-205, or the pair miR-103
and miR-126 linked to lung cancer in any way (Table 8).
In addition, from the miR2Disease [60], a manually various
human diseases, the five miRNAs (miR-98, miR-205, miR-
451, miR-126 and let-7a) have been found to be associated
with lung cancer.
Discussion
As described, this work applied a new rule discovery and
distance separation technique to discover 2-miRNA and 3-
miRNA 100%-frequency rules for lung SCC diagnosis. We
constructed a data set consisting of 19 important miRNAs
by projecting 5 plasma miRNA biomarkers onto the whole
list of 328 miRNAs ordered by gain ratio. Classification
performance on this data set is better than on other data
sets. This study can also provide knowledge for us to
develop potential non-invasive or minimally invasive diag-
nostic biomarkers for early lung cancer diagnosis. Of the 5
previously intensively studied plasma miRNAs, three of
them (miR-21, miR-126 and miR-182) have been consid-
ered to form our diagnostic rules for lung tissue diagnosis.
So, these 2-miRNA and 3-miRNA rules and the corre-
sponding miRNAs identified from the tumor tissues may
be good plasma miRNA biomarkers as well.
The present study suggests that a minimal 2-miRNA
or 3-miRNA rule can distinguish lung SCC tissues from
normal tissues. These rules are entirely new, because
complex diseases are often affected by various miRNAs
rather than a single miRNA, and single-miRNA rules
are insufficient for accurate diagnosis.
The advantage of the method presented here can be
extended to the study of biomarkers identification in
lung cancer prognosis. Also, we can validate the prog-
nostic utility of these identified diagnostic biomarkers in
early lung cancer. In addition, the discovered rules and
distance separation technique would potentially be
applied to further investigation of biomarkers in other
cancer diagnosis and prognosis, including breast cancer,
pancreatic cancer, etc.
Table 6 The probability of different AUC values in the
1000 randomization tests.
2-miRNA AUCs Probability 3-miRNA AUCs Probability
≥ 0.9 0.177 ≥ 0.9 0.328
≥ 0.95 0.089 ≥ 0.95 0.19
≥ 0.98 0.035 ≥ 0.98 0.091
≥ 0.99 0.025 ≥ 0.99 0.062
≥ 0.998 0.009 ≥ 0.9975 0.02
≥ 0.999 0.007 ≥ 0.999 0.012
Table 7 The chromosomal location of the 13 miRNAs in
our 2D and 3D biomarker rules.
miRNAs Chr location miRNAs Chr location
let-7a-1,-2,-3 9q22.2,11q24.1, 22q13.3 miR-199a-1,-2 19p13.2, 1q23.2
miR-133a-1,-2 18q11.1,20q13.3
miR-21 17q23.2 miR-200c 12p13.31
miR-98 Xp11.2 miR-205 1q32.2
miR-100 11q24.1 miR-451 17q11.2
miR-126 9q34 miR-520a-AS 19q13.42
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Conclusions
Rule discovery followed by distance separation is a
powerful computational method for reliable identifica-
tion of miRNA biomarkers. The visualization of the
rules and the clear separation between the normal and
cancer samples by our rules will help biology experts for
their analysis and biological interpretation.
This work has illustrated computational difficulties of
multi-miRNA analysis of expression data, and presented
our effective approach to 2-miRNA or 3-miRNA bio-
marker discovery for lung SCC diagnosis. We proposed
a novel method to construct a committee of decision
trees which are subsequently used to derive 100%-fre-
quency rules containing 2 or 3 miRNAs. To detect more
reliable rules, we applied a Max-Min distance separation
technique to look for the clear boundaries between the
normal and cancer sample groups. The chromosomal
loci of the miRNAs in these rules are identified, and the
target genes of these biomarker miRNAs are also
obtained from databases to determine the common
mRNAs. These common target genes are then linked to
diseases. As future work, the proposed method can be
applied for plasma biomarkers identification, and it can
be taken for diagnosis and prognosis studies related to
other cancers.
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